Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia

Adam J. Guenzel, Matthew L. Hillestad, Dietrich Matern, Michael A Barry

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism caused by deficiency of propionyl-CoA carboxylase (PCC). This enzyme is composed of six PCCA and six PCCB subunits and mediates a critical step in catabolism of odd chain fatty acids and certain amino acids. Current treatment options for PA are limited to stringent dietary restriction of protein consumption and some patients undergo elective liver transplantation. We previously generated a hypomorphic model of PA, designated Pcca-/-(A138T), with 2% of wild-type enzyme activity that mimics many aspects of the human disease. In this study, we used the differing tissue tropisms of adeno-associated virus (AAV) to probe the ability of liver or muscle-directed gene therapy to treat systemic aspects of this disease that affects many cell types. Systemic therapy with muscle-biased AAV1, liver-biased AAV8, and broadly tropic AAVrh10 mediated significant biochemical corrections in circulating propionylcarnitine (C3) and methyl citrate by all vectors. The innate tissue bias of AAV1 and AAV8 gene expression was made more specific by the use of muscle-specific muscle creatine kinase (specifically MCK6) and hepatocyte-specific transthyretin (TTR) promoters, respectively. Under these targeted conditions, both vectors mediated significant long-term correction of circulating metabolites, demonstrating that correction of muscle and likely other tissue types in addition to liver is necessary to fully correct pathology caused by PA. Liver-specific AAV8-TTR-PCCA mediated better correction than AAV1-MCK-PCCA. These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease.

Original languageEnglish (US)
Pages (from-to)837-843
Number of pages7
JournalHuman Gene Therapy
Volume25
Issue number9
DOIs
StatePublished - Sep 1 2014

Fingerprint

Propionic Acidemia
Dependovirus
Biomarkers
Genetic Therapy
Muscles
propionylcarnitine
Prealbumin
Liver
Liver Transplantation
MM Form Creatine Kinase
Inborn Errors Metabolism
Inborn Genetic Diseases
Tropism
Dietary Proteins
Enzymes
Citric Acid
Serogroup
Hepatocytes
Fatty Acids
Pathology

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia. / Guenzel, Adam J.; Hillestad, Matthew L.; Matern, Dietrich; Barry, Michael A.

In: Human Gene Therapy, Vol. 25, No. 9, 01.09.2014, p. 837-843.

Research output: Contribution to journalArticle

Guenzel, Adam J. ; Hillestad, Matthew L. ; Matern, Dietrich ; Barry, Michael A. / Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia. In: Human Gene Therapy. 2014 ; Vol. 25, No. 9. pp. 837-843.
@article{24efb813d91545ffb05ea78c1904ed57,
title = "Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia",
abstract = "Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism caused by deficiency of propionyl-CoA carboxylase (PCC). This enzyme is composed of six PCCA and six PCCB subunits and mediates a critical step in catabolism of odd chain fatty acids and certain amino acids. Current treatment options for PA are limited to stringent dietary restriction of protein consumption and some patients undergo elective liver transplantation. We previously generated a hypomorphic model of PA, designated Pcca-/-(A138T), with 2{\%} of wild-type enzyme activity that mimics many aspects of the human disease. In this study, we used the differing tissue tropisms of adeno-associated virus (AAV) to probe the ability of liver or muscle-directed gene therapy to treat systemic aspects of this disease that affects many cell types. Systemic therapy with muscle-biased AAV1, liver-biased AAV8, and broadly tropic AAVrh10 mediated significant biochemical corrections in circulating propionylcarnitine (C3) and methyl citrate by all vectors. The innate tissue bias of AAV1 and AAV8 gene expression was made more specific by the use of muscle-specific muscle creatine kinase (specifically MCK6) and hepatocyte-specific transthyretin (TTR) promoters, respectively. Under these targeted conditions, both vectors mediated significant long-term correction of circulating metabolites, demonstrating that correction of muscle and likely other tissue types in addition to liver is necessary to fully correct pathology caused by PA. Liver-specific AAV8-TTR-PCCA mediated better correction than AAV1-MCK-PCCA. These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease.",
author = "Guenzel, {Adam J.} and Hillestad, {Matthew L.} and Dietrich Matern and Barry, {Michael A}",
year = "2014",
month = "9",
day = "1",
doi = "10.1089/hum.2014.012",
language = "English (US)",
volume = "25",
pages = "837--843",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia

AU - Guenzel, Adam J.

AU - Hillestad, Matthew L.

AU - Matern, Dietrich

AU - Barry, Michael A

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism caused by deficiency of propionyl-CoA carboxylase (PCC). This enzyme is composed of six PCCA and six PCCB subunits and mediates a critical step in catabolism of odd chain fatty acids and certain amino acids. Current treatment options for PA are limited to stringent dietary restriction of protein consumption and some patients undergo elective liver transplantation. We previously generated a hypomorphic model of PA, designated Pcca-/-(A138T), with 2% of wild-type enzyme activity that mimics many aspects of the human disease. In this study, we used the differing tissue tropisms of adeno-associated virus (AAV) to probe the ability of liver or muscle-directed gene therapy to treat systemic aspects of this disease that affects many cell types. Systemic therapy with muscle-biased AAV1, liver-biased AAV8, and broadly tropic AAVrh10 mediated significant biochemical corrections in circulating propionylcarnitine (C3) and methyl citrate by all vectors. The innate tissue bias of AAV1 and AAV8 gene expression was made more specific by the use of muscle-specific muscle creatine kinase (specifically MCK6) and hepatocyte-specific transthyretin (TTR) promoters, respectively. Under these targeted conditions, both vectors mediated significant long-term correction of circulating metabolites, demonstrating that correction of muscle and likely other tissue types in addition to liver is necessary to fully correct pathology caused by PA. Liver-specific AAV8-TTR-PCCA mediated better correction than AAV1-MCK-PCCA. These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease.

AB - Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism caused by deficiency of propionyl-CoA carboxylase (PCC). This enzyme is composed of six PCCA and six PCCB subunits and mediates a critical step in catabolism of odd chain fatty acids and certain amino acids. Current treatment options for PA are limited to stringent dietary restriction of protein consumption and some patients undergo elective liver transplantation. We previously generated a hypomorphic model of PA, designated Pcca-/-(A138T), with 2% of wild-type enzyme activity that mimics many aspects of the human disease. In this study, we used the differing tissue tropisms of adeno-associated virus (AAV) to probe the ability of liver or muscle-directed gene therapy to treat systemic aspects of this disease that affects many cell types. Systemic therapy with muscle-biased AAV1, liver-biased AAV8, and broadly tropic AAVrh10 mediated significant biochemical corrections in circulating propionylcarnitine (C3) and methyl citrate by all vectors. The innate tissue bias of AAV1 and AAV8 gene expression was made more specific by the use of muscle-specific muscle creatine kinase (specifically MCK6) and hepatocyte-specific transthyretin (TTR) promoters, respectively. Under these targeted conditions, both vectors mediated significant long-term correction of circulating metabolites, demonstrating that correction of muscle and likely other tissue types in addition to liver is necessary to fully correct pathology caused by PA. Liver-specific AAV8-TTR-PCCA mediated better correction than AAV1-MCK-PCCA. These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease.

UR - http://www.scopus.com/inward/record.url?scp=84907294206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907294206&partnerID=8YFLogxK

U2 - 10.1089/hum.2014.012

DO - 10.1089/hum.2014.012

M3 - Article

C2 - 25046265

AN - SCOPUS:84907294206

VL - 25

SP - 837

EP - 843

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 9

ER -